GENE Stock Overview
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.17 |
| 52 Week High | AU$5.90 |
| 52 Week Low | AU$1.80 |
| Beta | 0.37 |
| 1 Month Change | 17.84% |
| 3 Month Change | 47.27% |
| 1 Year Change | -42.88% |
| 3 Year Change | -83.27% |
| 5 Year Change | -79.81% |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
Genetic acquires AffinityDNA to bolster direct-to-consumer business
Jul 14Infinity Biologix launches Genetic Technologies' COVID-19 test
Jun 09Genetic Technologies launches COVID-19 risk test through partnership with Infinity Biologix
Jun 01Genetic Technologies’ COVID-19 risk test to be commercially available in U.S.
Apr 26Genetic Technologies appoints new CEO; Shares are up 8%
Jan 04Shareholder Returns
| GENE | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 10.1% | -3.7% | -3.1% |
| 1Y | -42.9% | -5.7% | 20.9% |
Return vs Industry: GENE underperformed the US Life Sciences industry which returned -5.7% over the past year.
Return vs Market: GENE underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| GENE volatility | |
|---|---|
| GENE Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GENE's share price has been volatile over the past 3 months.
Volatility Over Time: GENE's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 60 | Simon Morriss | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| GENE fundamental statistics | |
|---|---|
| Market cap | US$12.20m |
| Earnings (TTM) | -US$8.15m |
| Revenue (TTM) | US$6.56m |
1.9x
P/S Ratio-1.5x
P/E RatioIs GENE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENE income statement (TTM) | |
|---|---|
| Revenue | AU$10.24m |
| Cost of Revenue | AU$3.94m |
| Gross Profit | AU$6.30m |
| Other Expenses | AU$19.01m |
| Earnings | -AU$12.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 61.50% |
| Net Profit Margin | -124.08% |
| Debt/Equity Ratio | 0% |
How did GENE perform over the long term?
See historical performance and comparison